Federal Register / Vol. 65, No. 236 / Thursday, December 7, 2000 / Notices 76651

NCI encourages nomination of

candidates reflecting the diversity

sought on the DCLG. Nominations can

be made by organizations, including

local/regional and national groups, or

individuals, including self-nominations.

To receive a nomination package for the

DCLG, send your name, advocacy/

voluntary organization affiliation (if

any), address and phone number to the

Office of Liaison Activities, NCI, c/o

Palladian Partners, 1010 Wayne

Avenue, Suite 1200, Silver Spring, MD

20910, FAX (301) 650 8676.

Nominations must be postmarked by

February 15, 2001.

Dated: November 30, 2000.

LaVerne Stringfield,

Director, Office of Federal Advisory

Committee Policy, National Institutes of

Health.

[FR Doc. 00–31197 Filed 12–6–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by writing

to the indicated licensing contact at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

Immunoglobulin-G Constant Region

Fusion Proteins as Molecular Weight

Markers

Stephen V. Angeloni, Ph.D. (NIDDK)

DHHS Reference No. E–292–00/0,

Licensing Contact: Marlene Shinn;

301/496–7056 ext. 285; e-mail:

shinnm@od.nih.gov

The technology portrayed in this

invention is available through a

Biological Materials License as a

research tool and for use in diagnostic

tests. Current methods of protein

detection and size determination can be

made more efficient by the utilization of

more stable protein markers that cover

a wider range of molecular weights for

western blotting and other diagnostics

applications. As embodied in this

invention, construction of recombinant

proteins containing constant regions of

Immunoglobulin-G from mouse, rabbit

and other species, allow the production

of protein standards that can be detected

simultaneously on the same western

blot as the sample proteins. Such

markers will increase the accuracy in

determining sample protein size and in

combination with recombinant or

chemically labeled second antibodies,

will allow the detection of an increased

number of sample proteins

simultaneously on the same blot.

A Forward Mutational Assay for Use

With PhiX174 Transgenic Mice

Carrie R. Valentine (FDA), Heinrich V.

Malling (NIEHS), Bentley A. Fane

(Univ. of Arizona)

DHHS Reference No. E–254–00/0 filed

11 July, 2000, Licensing Contact:

Marlene Shinn; 301/496–7056 ext.

285; email: ms482m@nih.gov

The aforementioned invention is

currently available through a Biological

Materials License as a research tool.

This assay can detect 19 different base

substitutions at 13 different sites in gene

A of the PhiX174 transgene present in

the transgenic Malling mouse and is an

improvement over the previous

reversion assay, which was limited to

mutation at a single site. The ability to

detect mutations at multiple sites will

allow the detection of mutagenic test

compounds with affinity for different

sequence contexts, while retaining the

advantage of the inexpensive recovery

of this transgene, which is by

electroporation.

The evaluation of new drugs for their

potential for inducing mutations is a

necessary part of evaluating the safety of

pharmaceuticals or environmental

chemicals. One advantage of this assay

is that it may be automated to be

performed in microplate dishes. In

addition, this assay has the potential to

be utilized in a microarray system

because of the limited number of

possible mutations. Therefore, it would

be more rapid and less expensive than

the currently used transgenic systems.

Adult Human Dental Pulp Stem Cells in

vitro and in vivo

Dr. Songtao Shi et al. (NIDCR)

DHHS Reference No. E–233–00/0 filed

21 July 2000, Licensing Contact:

Marlene Shinn; 301/496–7056 ext.

285; e-mail: shinnm@od.nih.gov

Many individuals with ongoing and

severe dental problems are faced with

the prospect of permanent tooth loss.

Examples include dentinal degradation

due to caries or periodontal disease;

(accidental) injury to the mouth; and

surgical removal of teeth due to tumors

associated with the jaw. Clearly, a

technology that offers a possible

alternative to artificial dentures by

designing and transplanting a set of

living teeth fashioned from the patient’s

own pulp cells would greatly improve

the individual’s quality of life.

The NIH announces a new technology

wherein dental pulp stem cells from an

individual’s own postnatal dental pulp

tissue (one or two wisdom teeth) can

potentially be used to engineer healthy

living teeth. This technology is based

upon the discovery of a subpopulation

of cells within normal human dental

pulp tissue that has the ability to grow

and proliferate in vitro. These (dental

pulp) stem cells can be induced under

defined culture conditions to form

calcified nodules in vitro and have been

shown to differentiate into a dentin/

pulp like structure in vivo.

PTH2 and PTH1 Receptor Ligands

Ted B. Usdin and Samuel R. Hoare

(NIMH)

DHHS Reference No. E–123–99/1 filed

15 June 2000, Licensing Contact:

Norbert Pontzer; 301/496–7735, ext.

284; e-mail: pontzern@od.nih.gov

Parathyroid hormone receptors found

on osteoblasts in bone and renal tubule

cells in kidney elevate blood calcium

levels when stimulated by parathyroid

hormone (PTH) and PTH-related protein

(PTHrP). Excessive secretion of PTH

from the parathyroid gland results in

primary hyperparathyroidism.

Production of PTHrP by various tumors

results in humoral hypercalcemia of

malignancy. In both of these conditions,

excessive blood calcium levels lead to

clinically significant morbidity. A

parathyroid hormone antagonist could

therefore have therapeutic value.

Until now, no effective antagonists for

the classical parathyroid hormone

receptor (PTH1 receptor) were known.

This invention describes a peptide

which binds with high affinity

(Kd = 1.3 ± 0.1 nM, dissociation T1/2 = 14

min.) and acts as purely competitive

antagonist at the PTH1 receptor. This

novel peptide is related to

76652 Federal Register / Vol. 65, No. 236 / Thursday, December 7, 2000 / Notices

tuberoinfundibular peptides of 39

residues (TIP39), also described in this

invention, which binds to a related

receptor. Deletion of amino acids from

the N-terminus of TIP39 resulted in the

high affinity PTH1 receptor antagonist

peptide described here. This peptide

may be used therapeutically to treat

excessive blood calcium caused by PTH

or PTHrP, other pathology caused by

PTHrP, to demonstrate the utility of

parathyroid hormone receptor

antagonism in the treatment of

hypercalcemia or other conditions, or to

help screen for other antagonists at the

parathyroid hormone receptor.

Dated: November 29, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 00–31216 Filed 12–6–00; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Center for Complementary &

Alternative Medicine; Notice of Closed

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Center for

Complementary and Alternative Medicine

Special Emphasis Panel NCCAM AIDS SEP–

H08.

Date: December 12, 2000.

Time: 12:00 p.m. to 2:00 p.m.

Agenda: To review and evaluate grant

applications.

Place: Democracy II, Ste. 106, Bethesda,

MD 20892, (Telephone Conference Call).

Contact Person: Cecelia Maryland, Grants

Technical Assistant, National Center for

Complementary and Alternative Medicine,

National Institutes of Health, Building 31,

Room 5B50, Bethesda, MD 20892, (301) 480–

2419.

Dated: November 30, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–31206 Filed 12–6–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood

Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Heart, Lung,

and Blood Institute Special Emphasis Panel,

SCOR-Impact of Injury on the Immature

Pulmonary Circulation.

Date: January 10, 2001.

Time: 8:30 am to 5 pm.

Agenda: To review and evaluate grant

applications.

Place: Holiday Inn—Chevy Chase,

Palladian East and Center Rooms, 5520

Wisconsin Avenue, Chevy Chase, MD 20815.

Contact Person: Deborah P. Beebe, PhD,

Chief, Rockledge Center II, 6701 Rockledge

Drive, Suite 7178, Bethesda, MD 20892–7924,

301/435/0270.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.233, National Center for

Sleep Disorders Research; 93.837, Heart and

Vascular Diseases Research; 93.838, Lung

Diseases Research; 93.839, Blood Diseases

and Resources Research, National Institutes

of Health, HHS)

Dated: November 28, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–31199 Filed 12–6–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood

Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 522b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Heart, Lung,

and Blood Institute Special Emphasis Panel.

Date: January 7–9, 2001.

Time: 7 pm to 6 pm.

Agenda: To review and evaluate grant

applications.

Place: Holiday Inn—Chevy Chase,

Palladian East and Center Rooms, 5520

Wisconsin Avenue, Chevy Chase, MD 20815.

Contact Person: Anne P Clark, PhD, NIH,

NHLBI, DEA, Review Branch, Rockledge II,

6701 Rockledge Drive, Room 7202, Bethesda,

MD 20892–7924, 301/435–0310.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.233, National Center for

Sleep Disorders Research; 93.837, Heart and

Vascular Diseases Research; 93.838, Lung

Diseases Research; 93.839, Blood Diseases

and Resources Research, National Institutes

of Health, HHS)

Dated: November 28, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–31200 Filed 12–6–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and

Digestive and Kidney Diseases; Notice

of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections